Glioma News and Research RSS Feed - Glioma News and Research

Glioma is a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).
Brain cancer patients can benefit from Rapamycin drug

Brain cancer patients can benefit from Rapamycin drug

Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
One-two punch designed to knock out most dangerous brain cancer

One-two punch designed to knock out most dangerous brain cancer

University of Michigan Health System doctors have started testing a unique new approach to fighting brain tumors -- one that delivers a one-two punch designed to knock out the most dangerous brain cancer. [More]
Use of VISIUS iMRI in brain tumor surgery results in complete tumor removal

Use of VISIUS iMRI in brain tumor surgery results in complete tumor removal

IMRIS Inc. today announced that a recently published article in the journal Neurosurgery is the highest level clinical evidence to show that the use of VISIUS® intraoperative MRI in brain tumor surgery results in complete tumor removal in more patients with glioma tumors. [More]
Research validates Myc inhibition as effective therapeutic strategy for glioma

Research validates Myc inhibition as effective therapeutic strategy for glioma

Research led by the Vall d'Hebron Institute of Oncology (VHIO) evidence the most conclusive preclinical results to-date validating Myc inhibition as a therapeutic strategy in glioma - a highly agressive tumor type that notoriously outsmarts current anti-cancer therapies. [More]
Imaging system rapidly detects molecular marker in brain gliomas, enables removal of tumor

Imaging system rapidly detects molecular marker in brain gliomas, enables removal of tumor

During tumor surgery, surgeons work to remove tumor tissue without damaging surrounding healthy tissue. [More]
Findings show how galectin-1 protein plays key role in high grade malignant gliomas

Findings show how galectin-1 protein plays key role in high grade malignant gliomas

Brain tumors fly under the radar of the body's defense forces by coating their cells with extra amounts of a specific protein, new research shows. [More]
Induced immunorejection may eliminate tumors post-cell transplantation

Induced immunorejection may eliminate tumors post-cell transplantation

Recent studies have shown that transplanting induced pluripotent stem cell-derived neural stem cells (iPS-NSCs) can promote functional recovery after spinal cord injury in rodents and non-human primates. However, a serious drawback to the transplantation of iPS-NSCs is the potential for tumor growth, or tumorogenesis, post-transplantation. [More]
Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the past 12 months. [More]
Research finding offers potential therapeutic avenues for glioblastoma

Research finding offers potential therapeutic avenues for glioblastoma

Invading glioblastoma cells may hijack cerebral blood vessels during early stages of disease progression and damage the brain's protective barrier, a study in mice indicates. This finding could ultimately lead to new ways to bring about the death of the tumor, as therapies may be able to reach these deadly cells at an earlier time point than was previously thought possible. [More]
Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected. [More]
BRI to present clinical-stage product data at International Symposium on Pediatric Neuro-Oncology

BRI to present clinical-stage product data at International Symposium on Pediatric Neuro-Oncology

The Burzynski Research Institute, Inc. (BRI) announced today that it will present data on two of the Company's clinical-stage product candidates, Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections (Astugenal®), at the 16th International Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to July 2, 2014. [More]
Scientists report first successful step toward vaccine that targets mutation in brain cancer

Scientists report first successful step toward vaccine that targets mutation in brain cancer

Astrocytomas and oligodendrogliomas are subtypes of a brain cancer called 'glioma'. These incurable brain tumors arise from glial cells, a type of support cell found in the central nervous system. [More]
EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor. [More]
Researchers shed new light on how gliomas cells migrate in brain and cause devastating tumors

Researchers shed new light on how gliomas cells migrate in brain and cause devastating tumors

Researchers at the University of Alabama at Birmingham have shed new light on how cells called gliomas migrate in the brain and cause devastating tumors. [More]
New class of tumor-targeting agents can seek out dozens of solid tumors

New class of tumor-targeting agents can seek out dozens of solid tumors

Scientists at the University of Wisconsin Carbone Cancer Center (UWCCC) report that a new class of tumor-targeting agents can seek out and find dozens of solid tumors, even illuminating brain cancer stem cells that resist current treatments. [More]
Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that it has initiated the Phase III trial of DCVax-L in Germany. [More]
Gene variants that lead to longer telomeres boost brain cancer risk

Gene variants that lead to longer telomeres boost brain cancer risk

New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas. [More]
Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine. [More]
Collaborative research effort produces new genetic insights into brainstem glioma

Collaborative research effort produces new genetic insights into brainstem glioma

A collaborative effort between Duke Medicine researchers and neurosurgeons and scientists in China has produced new genetic insights into a rare and deadly form of childhood and young adult brain cancer called brainstem glioma. [More]